164 related articles for article (PubMed ID: 35905418)
1. Decision-Making Scoring System for the Repetition of Conventional Transarterial Chemoembolization in Patients With Inoperable Hepatocellular Carcinoma.
Bannangkoon K; Hongsakul K; Tubtawee T; Janjindamai P; Akkakrisee S; Piratvisuth T; Geater A
Clin Transl Gastroenterol; 2022 Jul; 13(7):e00506. PubMed ID: 35905418
[TBL] [Abstract][Full Text] [Related]
2. Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat?
Chen S; Peng Z; Zhang Y; Chen M; Li J; Guo R; Li J; Li B; Mei J; Feng S; Kuang M
Radiology; 2021 Mar; 298(3):680-692. PubMed ID: 33464183
[TBL] [Abstract][Full Text] [Related]
3. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
4. Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma.
Kloeckner R; Pitton MB; Dueber C; Schmidtmann I; Galle PR; Koch S; Wörns MA; Weinmann A
J Vasc Interv Radiol; 2017 Jan; 28(1):94-102. PubMed ID: 27562621
[TBL] [Abstract][Full Text] [Related]
5. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
Zhang ZS; Li HZ; Ma C; Xiao YD
BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
[TBL] [Abstract][Full Text] [Related]
6. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.
Li H; Wu F; Duan M; Zhang G
Medicine (Baltimore); 2019 May; 98(21):e15314. PubMed ID: 31124925
[TBL] [Abstract][Full Text] [Related]
7. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
8. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
Tang J; Huang Z; Xu J; Lv Q; Wang P
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
[TBL] [Abstract][Full Text] [Related]
10. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
11. Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma.
Mähringer-Kunz A; Kloeckner R; Pitton MB; Düber C; Schmidtmann I; Galle PR; Koch S; Weinmann A
Cardiovasc Intervent Radiol; 2017 Jul; 40(7):1017-1025. PubMed ID: 28197830
[TBL] [Abstract][Full Text] [Related]
12. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function.
Nam JY; Choe AR; Sinn DH; Lee JH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Lee JM; Chung JW; Choi SY; Lee JK; Baek SY; Lee HA; Kim TH; Yoo K
BMC Cancer; 2020 Jun; 20(1):504. PubMed ID: 32487089
[TBL] [Abstract][Full Text] [Related]
13. The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment: A Cohort Study in Taiwan.
Tseng CL; Lai WJ; Huang CJ; Huang YH; Su CW; Lee IC; Tseng HS; Li CP; Lee RC; Lin HC; Chao Y
Medicine (Baltimore); 2015 Nov; 94(47):e1659. PubMed ID: 26632677
[TBL] [Abstract][Full Text] [Related]
14. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
[TBL] [Abstract][Full Text] [Related]
15. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
16. Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma.
Mähringer-Kunz A; Weinmann A; Schmidtmann I; Koch S; Schotten S; Pinto Dos Santos D; Pitton MB; Dueber C; Galle PR; Kloeckner R
BMC Cancer; 2018 Apr; 18(1):489. PubMed ID: 29703174
[TBL] [Abstract][Full Text] [Related]
17. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.
Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Hao Y; Zheng X; Li C; Li W
Cancer Biol Ther; 2022 Dec; 23(1):89-95. PubMed ID: 35230928
[TBL] [Abstract][Full Text] [Related]
18. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
[TBL] [Abstract][Full Text] [Related]
19. Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE).
de Baere T; Ronot M; Chung JW; Golfieri R; Kloeckner R; Park JW; Gebauer B; Kibriya N; Ananthakrishnan G; Miyayama S
Cardiovasc Intervent Radiol; 2022 Oct; 45(10):1430-1440. PubMed ID: 35978174
[TBL] [Abstract][Full Text] [Related]
20. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
